Anthera Pharmaceuticals has selected the Merck BioManufacturing Network to manufacture the large-scale GMP clinical and pre-commercial supplies of A-623, an investigational peptibody in development for autoimmune diseases. “Establishing a rapid and high quality supply of A-623 for our current and future clinical programs is a critical element of our strategic plan and provides a number of potential development options,” said Paul F. Truex, president and chief executive officer of ...